Summit and Sarepta to collaborate on muscular dystrophy drug

October 4, 2016 11:29 AM

1 0

Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.

Summit will get $40 million up front and could receive up to $522 million in milestone payments, they said.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page